Clinical characteristics of eosinophilic phenotype of chronic obstructive pulmonary disease


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Modern understanding of chronic obstructive pulmonary disease (COPD) is characterized by a variety of clinical and functional characteristics of the disease and the heterogeneity of the inflammatory response. Inflammation is one of the key mechanisms of COPD pathophysiology, and, respectively, an important target for pharmacological intervention. Eosinophilic inflammation in COPD is associated with frequent exacerbations and high rates of disease progression. Recent studies show significant effects of eosinophilic inflammation not only on the course and prognosis of patients with COPD, but also on the therapeutic response. Eosinophilic phenotype of COPD is predictor of the efficacy of inhaled corticosteroids that should be considered when selecting pharmacotherapy of this disease.

Full Text

Restricted Access

About the authors

I. N Trofimenko

Branch of FSBEI FPE RMACPE of RMH

Email: tinll@mail.ru
MD, Assistant Professor at the Department of Clinical Allergology and Pulmonology IGNAPGE

B. A Chernyak

Branch of FSBEI FPE RMACPE of RMH

Department of Clinical Allergology and Pulmonology ISMAPGE

References

  1. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J. Clin. Invest. 2008;118(11):3546-56.
  2. Barnes PJ. Mechanisms in COPD: differences from asthma. Chest. 2000;117(Suppl. 2):10-4.
  3. McDonald V.M., Higgins I., WoodL.G., Gibson PG. Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense? Thorax. 2013;68(7):691-94.
  4. Leigh R., Pizzichini M.M., Morris M.M., Maltais F., Hargreave F.E., Pizzichini E. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur. Respir. J. 2006;27(5):964-71.
  5. Bafadhel M., Greening N.J., Harvey-Dunstan T.C., Williams J.E., Morgan M.D., Brightling C.E., Hussain S.F., Pavord I.D., Singh S.J., Steiner M.C. Blood Eosinophils and Outcomes in Severe Hospitalized Exacerbations of COPD. Chest. 2016;150(2):320-28.
  6. Bafadhel M., McKenna S., Terry S., Mistry V., Reid C., Haldar P., McCormick M., Haldar K., Kebadze T., Duvoix A., Lindblad K., Patel H., Rugman P., Dodson P., Jenkins M., Saunders M., Newbold P., Green R.H., Venge P., Lomas D.A., Barer M.R., Johnston S.L., Pavord I.D., Brightling C.E. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am. J. Respir. Crit. Care Med. 2011;184:662-71.
  7. Singh D., Kolsum U., Brightling C.E., Locantore N., Agusti A., Tal-Singer R. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur. Respir. J. 2014;44:1697-700.
  8. Cosio B.G., Soriano J.B., Lopez-Campos J.L., Calle-Rubio M., Soler-Cataluna J.J., de-Torres J.P. Defining the asthma - COPD overlap syndrome in a COPD cohort. Chest. 2015;307(8):980251.7
  9. Negewo N.A., McDonald V.M., Baines K.J., Wark P.A., Simpson J.L., Jones P.W., Gibson P.G. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD. Int. J. COPD. 2016;11:1495-504.
  10. Eltboli O., Mistry V., Barker B., Brightling C.E. Relationship between blood and bronchial submucosal eosinophilia and reticular basement membrane thickening in chronic obstructive pulmonary disease. Respirology. 2015;20(4):667-70.
  11. Westerhof G.A., Korevaar D.A., Amelink M., de Nijs S.B., de Groot J.C., Wang J., Weersink E.J., en Brinke A., Bossuyt P.M., Bel E.H. Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes. Eur. Respir. J. 2015;46(3):688-96.
  12. Zhang X.Y., Simpson J.L., Powell H., Zhang X.Y., Simpson J.L., Powell H., Yang I.A., Upham J.W., Reynolds P.N., Hodge S., James A.L., Jenkins C., Peters M.J., Lin J.T., Gibson P.G. Full blood count parameters for the detection of asthma inflammatory phenotypes. Clin. Exp. Allergy 2014;44(9):1137-45.
  13. Fowler S.J., Tavernier G., Niven R. High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma. J. Allergy Clin. Immunol. 2015;135(3):822-24.
  14. Pavord I.D., Lettis S., Locantore N., Pascoe S., Jones P.W., Wedzicha J.A., Barnes N.C. Blood eosinophils and inhaled corticosteroid/longacting ß-2 agonist efficacy in COPD. Thorax. 2016;71:118-25.
  15. Pascoe S., Locantore N., Dransfield M.T., Barnes N.C., Pavord I.D. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir. Med. 2015;3:435-42.
  16. Barnes N.C., Sharma R., Lettis S., Calverley P.M. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur. Respir. J. 2016;47(5):1374-82.
  17. Хроническая обструктивная болезнь легких. Клинические рекомендации. 2016. URL: http://spulmo.ru/obrazovatelnye-resursy/ federalnye-klinicheskie-rekomendatsii/
  18. Watz H., Tetzlaff K., Wouters E.F., Kirsten A., Magnussen H., Rodriguez-Roisin R., Vogelmeier C., Fabbri L.M., Chanez P., Dahl R., Disse B., Finnigan H., Calverley P.M. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir. Med. 2016;4(5):390-98.
  19. Hospers J.J., Schouten J.P., Weiss S.T., Rijcken B., Postma D.S. Asthma attacks with eosinophilia predict mortality from chronic obstructive pulmonary disease in a general population sample. Am. J. Respir. Crit. Care Med. 1999;160:1869-74.
  20. Hospers J.J., Schouten J.P., Weiss S.T., Postma D.S., Rijcken B. Eosinophilia is associated with increased all-cause mortality after a follow-up of 30 years in a general population sample. Epidemiology. 2000;11:261-68.
  21. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, Global Initiative for Chronic Obstructive Lung Disease (2010). www.goldcopd.org
  22. Barnes P.J. Glucocorticosteroids: current and future directions. Br. J. Pharmacol. 2011;163(1):29-43.
  23. Dong Y.H., Chang C.H., Lin Wu F.L., Shen L.J., Calverley P.M., Lofdahl C.G., Lai M.S., Mahler D.A. Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: systematic review and meta-analysis of randomized controlled trials. a systematic review and metaanalysis of randomized controlled trials. Chest. 2014;145(6):1286-97.
  24. Kew K.M., Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2014;10(3):CD010115.
  25. Magnussen H., Disse B., Rodriguez-Roisin R., Kirsten A., Watz H., Tetzlaff K., Towse.L, Finnigan H., Dahl R., Decramer M., Chanez P., Wouters E.F., Calverley P.M.; WISDOM Investigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N. Engl. J. Med. 2014;371(14):1285-94.
  26. Pavord I.D., Agusti A. Blood eosinophil count: a biomarker of an important treatable trait in patients with airway disease. Eur. Respir. J. 2016;47(5):1299-303.
  27. Hizawa N. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes. Int. J. Chron. Obstruct. Pulmon. Dis. 2015: 1093-102.
  28. Kerwin E. A new alphabet for COPD care. Eur. Respir. J. 2016;48(4):972-75.
  29. Couillard S., Larivee P., Courteau J., Vanasse A. Eosinophils in chronic obstructive pulmonary disease exacerbations are associated with increased readmissions. Chest. 2016: S0012-3692(16)60762-6.
  30. Pavord I.D., Lettis S., Anzueto A., Barnes N. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respir. Med. 2016;4(9):731-41.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies